KATU-TV reports on staff shortages at hospitals, including OHSU, across the state.

The Bend Bulletin cites OHSU forecast in a story noting that the surge in COVID-19 cases will likely last into the fall.

Gopal Allada, M.D., says: “Now that we’re dealing with delta, we really need to get those vaccination rates to go a lot higher."

The Boston Globe features retired OHSU neurologist Daniel Gibbs, M.D., in a story about a new FDA-approved drug for Alzheimer’s disease. Gibbs, who has Alzheimer’s and experienced severe side effects while participating in a clinical trial for the drug in 2017, says: “I would argue that in the first year or so, administration of the drug should be limited to [providers] with experience with the drug, not just any guy with a shingle.”

Fortune magazine notes that Miranda Lim, M.D., Ph.D., is at the forefront of clinical care and research involving the importance of sleep in potentially staving off cognitive decline: “We used to think that sleep problems were just another symptom of Alzheimer’s. Our big discovery was that the lack of sleep involves brain processes that may develop into the disease.”

Kaiser Permanente becomes the second Oregon health system, after OHSU, to announce they will require employees to be vaccinated against COVID-19 or obtain an approved exemption.

Story about irritable bowel syndrome cites OHSU assessment that women in the U.S. are twice as likely to have IBS as men.

Story about an outbreak of breakthrough cases in a South Dakota nursing home cites laboratory research by OHSU linking age with immune response; Fikadu Tafesse, Ph.D., says: “Our older populations are potentially more susceptible to the variants even if they are vaccinated. The good news is that our vaccines are really strong.”

Peter Graven, Ph.D., says that people must start wearing masks now if the state is to avoid an even more rapid rise in infections.

In an op-ed by Jalal Baig, M.D., that argues vaccinating more people overall would go farther to beat the pandemic than providing booster shots of the COVID-19 vaccine, Mark Slifka, Ph.D., is quoted as saying: “We know the antibody response from these vaccinations is waning, but we don’t know what the protective threshold is. We just don’t have enough information on these mRNA vaccines.”